Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on ...

Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including ...

Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.